Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.